当前位置:首页 > 报告详情

一次性产品的前景、趋势和未来市场.pdf

上传人: 张** 编号:158296 2024-03-31 52页 3.02MB

1、OUTLOOK,TRENDS&FUTURE MARKETS FOR SINGLE-USECollaboration,technology&innovation:shaping the Collaboration,technology&innovation:shaping the future of singlefuture of single-use use Tuesday July 11th 2023Big Picture Outlook and TrendsSINGLE USE IS DEFINITELY MAINSTREAMINDUSTRY IS MATURING,GETTING MOR

2、E EFFICIENT EXPECTING ITS SUPPLIERS TO SUPPORT PRODUCTIVITYTop Options for Bioreactor Platforms at Commercial Commercial ScaleScale,2023Estimated Percentage of Facilities Unit Operations that are“Single-Use or Disposable”2023 83%of Chinas Upstream BioManufacturing is Single Use New Bioprocessing is

3、mostly SUS at clinical scale.(Chinas bioprocess industry is mostly new).Source:BioPlans 2nd Annual:Chinas Position in Global BioManufacturing A Comparison of Chinas Emerging Position vs Established Regions Manufacturing Capacity and ProductionSingle-Use Vendor Satisfaction,2008-20231717-Year,Percent

4、ageYear,Percentage-point point Increase in Usage of Increase in Usage of DisposablesDisposablesAll Stages R&D&Manufacture,2006All Stages R&D&Manufacture,2006-20232023(Note:Not growth in sales,this is growth in application first usage within a facility)Post-COVID,Whats Driving the Industry?CAPACITY C

5、ONSTRAINTS ARE RETURNING TO NORMALLOOKING TO SINGLE USE TO ADDRESS CAPACITY CHALLENGESINCREASING EXPENDITURES ON SUS20 Years:Capacity Constraints Trends(2004-2023)COVID Severe Constraints 2021-2022Post-COVID 2023I believe our facility is experiencing production capacity constraints todayKey Areas to

6、 Address to Avoid Capacity Constraints(2006-2023)If this industry is to avoid significant capacity constraints,the most important areas to address are:Changes in Bioprocess Consumables OrderingSuppliers vs Biopharmas PerspectivesBiomanufacturer Facility Changes in Ordering for Bioprocess Supplies 20

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要讨论了单次使用技术在生物制造领域的现状、趋势和未来市场。关键数据包括:2023年,83%的中国上游生物制造采用单次使用技术;大部分新的生物工艺在临床试验规模上都是单次使用的。文章指出,生物工艺行业正在成熟,变得更加高效,期待供应商支持生产力。单次使用技术的使用在各个研发和制造阶段都有显著增长。后COVID时代,行业面临产能挑战,寻求单次使用技术解决。为避免产能约束,重要的是改变生物工艺消耗品的订购方式,以及供应商和生物制药商的视角。预计竞争将继续增加,从而降低价格。未来市场方面,文章提到了几个关键的时间点,如2023年、2024年等,以及一些具体的公司,如Pfizer、GSK等。文章还提到了一些新兴的生物工艺支出领域,以及单次使用技术在细胞治疗领域的改进需求。最后,文章提到了一些行业面临的挑战,如供应链问题、价格竞争等。
"单次使用技术未来趋势如何?" "生物制药行业如何应对产能挑战?" "新冠疫情后,生物工艺供应链发生了哪些变化?"
客服
商务合作
小程序
服务号
折叠